Bone-modifying agents (BMAs) for bone metastases are commonly prescribed for many years even though randomized clinical trials are only 1–2 years in duration. A systematic review on the risk-benefit of BMA use for > 2 years in breast cancer or castrate-resistant prostate cancer was conducted.
MEDLINE, Embase, and Cochrane databases were searched (1970–February 2019) for randomized and observational studies, and case series reporting on BMA efficacy (skeletal-related events and quality of life) and toxicity (osteonecrosis of the jaw, renal impairment, hypocalcemia, and atypical femoral fractures) beyond 2 years.
Of 2107 citations, 64 studies were identified. Three prospective and 9 retrospective studies were eligible. Data beyond 2 years was limited to subgroup analyses in all studies. Only one study (n = 181) reported skeletal-related event rates based on bisphosphonate exposure, with decreased rates from 27.6% (0–24 months) to 15.5% (> 24 months). None reported on quality of life. All 12 studies (denosumab (n = 948), zoledronate (n = 1036), pamidronate (n = 163), pamidronate-zoledronate (n = 522), ibandronate (n = 118)) reported ≥ 1 toxicity outcome. Seven bisphosphonate studies (n = 1077) and one denosumab study (n = 948) reported on osteonecrosis of the jaw. Across three studies (n = 1236), osteonecrosis of the jaw incidence ranged from 1 to 4% in the first 2 years to 3.8–18% after 2 years. Clinically significant hypocalcemia ranged from 1 to 2%. Severe renal function decline was ≤ 3%. Atypical femoral fractures were rare.
Evidence informing the use of BMA beyond 2 years is heterogeneous and based on retrospective analysis. Prospective randomized studies with greater emphasis on quality of life are needed.
PROSPERO registration number
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588–1594
Hernandez RK, Wade SW, Reich A, Pirolli M, Liede A, Lyman GH (2018) Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer 18:44. https://doi.org/10.1186/s12885-017-3922-0
Moretto P, Hutton B, Kuchuk I, Canil CM, Ng TL, Addison CL, Clemons MJ (2013) Skeletal-related events (SRE) and bone-targeted agents for metastatic prostate cancer: are we changing outcomes? JCO 31:e16074–e16074. https://doi.org/10.1200/jco.2013.31.15_suppl.e16074
Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL, Clemons M (2013) Incidence, consequences and treatment of bone metastases in breast cancer patients—experience from a single cancer centre. J Bone Oncol 2:137–144. https://doi.org/10.1016/j.jbo.2013.09.001
Clemons M, Gelmon KA, Pritchard KI, Paterson AHG (2012) Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol 19:259–268. https://doi.org/10.3747/co.19.1011
Holen I, Coleman RE (2010) Bisphosphonates as treatment of bone metastases. Curr Pharm Des 16:1262–1271
Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377–387
Van Poznak C, Somerfield MR, Barlow WE et al (2017) Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update. J Clin Oncol 35:3978–3986. https://doi.org/10.1200/JCO.2017.75.4614
Gradishar WJ, Anderson BO, Abraham J (2019) NCCN breast cancer guidelines. Breast Cancer 217
Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Reitsma DJ, Kennedy I, Allan SG, Mellars K (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335:1785–1791. https://doi.org/10.1056/NEJM199612123352401
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822. https://doi.org/10.1016/S0140-6736(10)62344-6
Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082–3092. https://doi.org/10.1016/j.ejca.2012.08.002
Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139. https://doi.org/10.1200/JCO.2010.29.7101
Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O’Connor T, Velasco MR Jr, Weckstein D, O’Mara A, Loprinzi CL, Shapiro CL (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 317:48–58. https://doi.org/10.1001/jama.2016.19425
Hortobagyi GN, Van Poznak C, Harker WG et al (2017) Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncol 3:906–912. https://doi.org/10.1001/jamaoncol.2016.6316
Guarneri V, Donati S, Nicolini M, Giovannelli S, D'Amico R, Conte PF (2005) Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 10:842–848. https://doi.org/10.1634/theoncologist.10-10-842
Henk H, Teitelbaum A, Kaura S (2012) Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid. Curr Med Res Opin 28:1119–1127. https://doi.org/10.1185/03007995.2012.689254
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379:1926–1936. https://doi.org/10.1056/NEJMoa1810527
Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D (2019) Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381:307–316. https://doi.org/10.1056/NEJMoa1903765
Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B (2017) Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL Study. Eur Urol 71:151–154. https://doi.org/10.1016/j.eururo.2016.07.032
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, de Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, COU-AA-302 Investigators (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152–160. https://doi.org/10.1016/S1470-2045(14)71205-7
Ng T, Awan AA, Clemons MJ et al (2019) Efficacy and safety for use of bone modifying agents beyond 2 years of treatment in breast cancer and castration-resistant prostate cancer with bone metastases. PROSPERO 2019:CRD42019126813
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097
Higgins JPT, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928
Wells G, Shea B, O’Connell D, et al (2009) The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses
Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 23:60–63. https://doi.org/10.1136/bmjebm-2017-110853
Stopeck AT, Fizazi K, Body J-J, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A (2016) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24:447–455. https://doi.org/10.1007/s00520-015-2904-5
Pecherstorfer M, Rivkin S, Body J-J, Diel I, Bergström B (2006) Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig 26:315–322. https://doi.org/10.2165/00044011-200626060-00002
Bal O, Oksuzoglu B, Dogan M, Durnali A, Uyeturk U, Demirci A, Arslan UY, Ekinci AS, Yildirim N, Alkis N, Kilic S (2019) Long-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefit. Ir J Med Sci. https://doi.org/10.1007/s11845-019-02120-6
Ding X, Fan Y, Ma F, Li Q, Wang J, Zhang P, Yuan P, Xu B (2012) Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis. Breast 21:544–549. https://doi.org/10.1016/j.breast.2012.04.008
Dincer M, Altundag K, Harputluoglu H, Aksoy S, Cengiz M, Gullu I (2008) Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases. Med Oncol 25:356–359. https://doi.org/10.1007/s12032-008-9045-3
Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587. https://doi.org/10.1200/JCO.2005.02.8670
Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antràs L, Smith M, Neary MP, Duh MS (2007) The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 109:1090–1096. https://doi.org/10.1002/cncr.22504
Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suárez MA, Aguiar Morales J (2007) Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 18:556–560. https://doi.org/10.1093/annonc/mdl408
Brufsky AM, Sereika SM, Mathew A, Tomifumi O, Singh V, Rosenzweig M (2013) Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study. Breast J 19:504–511. https://doi.org/10.1111/tbj.12152
Nakata E, Sugihara S, Yamashita N, Osumi S (2017) The incidence of atypical femoral fractures in breast cancer patients with bone metastases who received bisphosphonate treatment. J Orthop Sci 22:946–950. https://doi.org/10.1016/j.jos.2017.04.011
Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14:663–670. https://doi.org/10.1016/S1470-2045(13)70174-8
Clemons MJ, Ong M, Stober C et al (2019) A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer. JCO 37:11501–11501. https://doi.org/10.1200/JCO.2019.37.15_suppl.11501
We would like to thank Ms. Risa Shorr, information specialist for designing and executing the search strategy for this systematic review.
Availability of data and material
All supporting data is included in the manuscript and appendix. A summary of the protocol has been uploaded to PROSPERO.
Conflict of interest
The authors declare that they have no relevant conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ng, T.L., Tu, M.M., Ibrahim, M.F.K. et al. Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. Support Care Cancer (2020). https://doi.org/10.1007/s00520-020-05556-0
- Bone metastases
- Skeletal-related events
- Systematic review